Evidence map›Paper›PMID 25112870›Full record

ArticleThe Journal of biological chemistry2014

Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Zhifei Shao, John Morser, Lawrence L K Leung

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Methods to Investigate Thrombin Cleavage of Osteopontin (OPN).Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zhifei ShaoDivision of Hematology, Stanford University School of Medicine, Stanford, California 94305 and; Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304.
John MorserDivision of Hematology, Stanford University School of Medicine, Stanford, California 94305 and; Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304.
Lawrence L K LeungDivision of Hematology, Stanford University School of Medicine, Stanford, California 94305 and; Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304. Electronic address: lawrence.leung@stanford.edu.
VA Palo Alto Health Care System · USStanford University · US

Funding

T32 Training Program in Mechanisms and Innovation in Vascular DiseaseT32HL098049 · NHLBI · STANFORD UNIVERSITY · PI Nicholas James Leeper, Philip S Tsao · 2010 to 2026
$6.3M
FUNCTIONAL MAPPING AND PROTEIN ENGINEERING OF THROMBINR01HL057530 · NHLBI · STANFORD UNIVERSITY · PI LEUNG, LAWRENCE L · 1999 to 2013
$4.2M
NHLBI NIH HHS 1T32HL098049NHLBI NIH HHS 5R01HL057530NHLBI NIH HHS R01 HL057530
6 · The paper itself

Abstract

Thrombin cleavage alters the function of osteopontin (OPN) by exposing an integrin binding site and releasing a chemotactic C-terminal fragment. Here, we examined thrombin cleavage of OPN in the context of dendritic cell (DC) migration to define its functional domains. Full-length OPN (OPN-FL), thrombin-cleaved N-terminal fragment (OPN-R), thrombin- and carboxypeptidase B2-double-cleaved N-terminal fragment (OPN-L), and C-terminal fragment (OPN-CTF) did not have intrinsic chemotactic activity, but all potentiated CCL21-induced DC migration. OPN-FL possessed the highest potency, whereas OPNRAA-FL had substantially less activity, indicating the importance of RGD. We identified a conserved (168)RSKSKKFRR(176) sequence on OPN-FL that spans the thrombin cleavage site, and it demonstrated potent pro-chemotactic effects on CCL21-induced DC migration. OPN-FLR168A had reduced activity, and the double mutant OPNRAA-FLR168A had even lower activity, indicating that these functional domains accounted for most of the pro-chemotactic activity of OPN-FL. OPN-CTF also possessed substantial pro-chemotactic activity, which was fully expressed upon thrombin cleavage and its release from the intact protein, because OPN-CTF was substantially more active than OPNRAA-FLR168A containing the OPN-CTF sequence within the intact protein. OPN-R and OPN-L possessed similar potency, indicating that the newly exposed C-terminal SVVYGLR sequence in OPN-R was not involved in the pro-chemotactic effect. OPN-FL and OPN-CTF did not directly bind to the CD44 standard form or CD44v6. In conclusion, thrombin cleavage of OPN disrupts a pro-chemotactic sequence in intact OPN, and its loss of pro-chemotactic activity is compensated by the release of OPN-CTF, which assumes a new conformation and possesses substantial activity in enhancing chemokine-induced migration of DCs.

Indexed as

ProteolysisAmino Acid MotifsAnimalsCell MovementDendritic CellsHumansHyaluronan ReceptorsMiceMice, KnockoutMonocyte Chemoattractant ProteinsOsteopontinThrombinCcl12 protein, mouseCD44 protein, humanCd44 protein, mouseHyaluronan ReceptorsMonocyte Chemoattractant ProteinsOsteopontinSpp1 protein, mouseThrombinChemokineDendritic CellMigrationOsteopontinThrombin

Identifiers

PMID25112870
PMCPMC4175350
OpenAlexW1980306298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.